Antibiotic and prednisolone therapy of erysipelas: A randomized, double blind, placebo-controlled study

被引:61
|
作者
Bergkvist, PI [1 ]
Sjobeck, K [1 ]
机构
[1] KRISTIANSTAD HOSP,DEPT INFECT DIS,KRISTIANSTAD,SWEDEN
关键词
D O I
10.3109/00365549709011834
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
112 patients admitted to hospital with a diagnosis of erysipelas, were randomized to 8 days treatment with prednisolone or placebo in addition to antibiotics. 108 patients received the study drugs and were evaluated for time to cure, which was the primary end-point. The median healing time was significantly shorter in the prednisolone group, 5 days, vs 6 days in the placebo group (p < 0.01). The 90th percentile healing time was 10.0 days in the prednisolone group vs 14.6 days in the control group, The prednisolone-treated patients had a median length of hospital stay (secondary end-point) of 5 days vs 6 for the placebo-treated (p < 0.01), The median treatment time with intravenous antibiotics (secondary end-point) was 4 days in the placebo group, which was 1 day longer than in the prednisolone group (p < 0.05), 13 patients, 7 of whom received placebo, relapsed during the observation period of 3 weeks, The frequency of side effects attributable to the study drug was not higher in the prednisolone group.
引用
收藏
页码:377 / 382
页数:6
相关论文
共 50 条
  • [31] A RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND-STUDY OF DANAZOL IN HEMOPHILIA-A
    MEHTA, J
    SINGHAL, S
    KAMATH, MV
    MEHTA, BC
    ACTA HAEMATOLOGICA, 1992, 88 (01) : 14 - 16
  • [32] BUSERELIN TREATMENT OF CRYPTORCHIDISM - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    BICA, DTG
    HADZISELIMOVIC, F
    JOURNAL OF UROLOGY, 1992, 148 (02): : 617 - 621
  • [33] CIAMEXONE IN ENDOCRINE ORBITOPATHY - A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    KAHALY, G
    LIEB, W
    MULLERFORELL, W
    MAINBERGER, M
    BEYER, J
    VOLLMAR, J
    STAIGER, C
    ACTA ENDOCRINOLOGICA, 1990, 122 (01): : 13 - 21
  • [34] Kratom and Pain Tolerance: A Randomized Placebo-Controlled, Double-Blind Study
    Vicknasingam, Balasingam
    Chooi, Weng Tink
    Rahim, Azlan Abdul
    Ramachandram, Dinesh
    Singh, Darshan
    Ramanathan, Surash
    Yusof, Nur Sabrina Mohd
    Zainal, Hadzliana
    Murugaiyah, Vikneswaran
    Gueorguieva, Ralitza
    Mansor, Sharif Mahsufi
    Chawarski, Marek C.
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 2020, 93 (02): : 229 - 238
  • [35] A randomized, double-blind, placebo-controlled study of lorazepam as premedication for bronchoscopy
    Maltais, F
    Laberge, F
    Laviolette, M
    CHEST, 1996, 109 (05) : 1195 - 1198
  • [36] Arbaclofen Placarbil in GERD: A Randomized, Double-Blind, Placebo-Controlled Study
    Vakil, Nimish B.
    Huff, F. Jacob
    Bian, Amy
    Jones, Drew S.
    Stamler, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (08): : 1427 - 1438
  • [37] Modafinil for fatigue in MS - A randomized placebo-controlled double-blind study
    Stankoff, B
    Waubant, E
    Confavreux, C
    Edan, G
    Debouverie, M
    Rumbach, L
    Moreau, T
    Pelletier, J
    Lubetzki, C
    Clanet, M
    NEUROLOGY, 2005, 64 (07) : 1139 - 1143
  • [38] Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
    Rammohan, KW
    Lynn, DJ
    NEUROLOGY, 2005, 65 (12) : 1995 - 1996
  • [39] A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis
    Carter, Melody C.
    Maric, Irina
    Brittain, Erica H.
    Bai, Yun
    Lumbard, Keith
    Bolan, Hyejeong
    Cantave, Daly
    Scott, Linda M.
    Metcalfe, Dean D.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 1004 - +
  • [40] A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia
    Sabe, L
    Salvarezza, F
    Cuerva, AG
    Leiguarda, R
    Starkstein, S
    NEUROLOGY, 1995, 45 (12) : 2272 - 2274